Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Reblozyl flops in a new anaemia use
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
